Allergen-specific immunotherapy. Analytic review of current international and Russian federal position papers


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription Access

Abstract

The article analyses the international position papers devoted to allergen-specific immunotherapy published in recent years. It also describes in details Russian federal guidelines, published in the 2013-2016 years and dedicated to allergen-specific immunotherapy as a method of treatment of IgE-mediated allergic diseases, as well as Russian federal guidelines. Detailed understanding of indications, contraindications, and usage of AIT in various clinical situations are widely discussed.

About the authors

O M Kurbacheva

Institute of Immunology

Email: kurbacheva@gmail.com
Moscow, Russia

K S Pavlova

Institute of Immunology

Moscow, Russia

M A Galitzkaya

Institute of Immunology

Moscow, Russia

References

  1. Гущин И.С., Курбачева О.М. Аллергия и аллергенспеци-фическая иммунотерапия. М.: «Фармарус Принт Медиа». 2010, 228 с.
  2. Bousquet J., Lockey R., Malling H.J. WHO Position Paper. Allergen immunotherapy: therapeutic vaccines for allergic diseases. Allergy. 1998, v. 53, p. 1-42.
  3. Calderon M.A., Alves B., Jacobson M. et al. Allergen injection immunotherapy for seasonal allergic rhinitis. Cochrane Database Syst. Rev. 2007, v. 24 (1): CD001936.
  4. Jutel M., Agache I., Bonini S. et al. International Consensus On (ICON) Allergy Immunotherapy (AIT). J. Allergy Clin. Immunol. 2015, v. 136 (3), p. 556-568.
  5. Normansell R., Kew K.M., Bridgman A.L. Sublingual immunotherapy for asthma. Cochrane Database Syst. Rev. 2015, v. 28 (8): CD011293.
  6. Radulvic S., Calderon M.A., Wilson D., Durham S. Sublingual immunotherapy for allergic rhinitis. Cochrane Database Syst. Rev. 2010, v. 8 (12): CD002893.
  7. Canonica G.W., Bachert C., Hellings P. et al. Allergen Immunotherapy (AIT): a prototype of Precision Medicine World Allergy Organ J. 2015, v. 10, p. 31.
  8. Jutel M., Agache I., Bonini S. et al. International Consensus On (ICON) Allergy Immunotherapy II: Mechanisms, standardization and pharmacoeconomics. J. Allergy Clin. Immunol. 2016, v. 137, p. 358-368.
  9. Canonica G.W, Baena Cagnani C.E., Bousquet J. et al. Recommendations for standardized clinical trials with Allergen Specific Immunotherapy for respiratory allergy. A statement of the World Allergy Organization (WAO) taskforce. Allergy. 2007, v. 62, p. 317-324.
  10. Pfaar O., Demoly P., Gerth van Wijk R. et al. EAACI. Recommendations for the standardization of clinical outcomes used in allergen immunotherapy trials for allergic rhinoconjunctivitis: an EAACI Position Paper. Allergy. 2014, v. 69 (7), p. 854-867.
  11. Rösner-Friese K., Kaul S., Vieths S., Pfaar O. Environmental exposure chambers in allergen immunotherapy trials: current status and clinical validation needs. J. Allergy Clin. Immunol. 2015, v. 135, p. 636-643.
  12. Bauer C.S., Rank M.A. Comparative efficacy and safety of subcutaneous versus sublingual immunotherapy. J. Allergy Clin. Immunol. 2014, v. 134, p. 65-765.
  13. Casale T.B., Stokes J.R. Immunotherapy: what lies beyond. J. Allergy Clin. Immunology. 2014, v. 133, p. 612-619.
  14. Von Moos S., Johansen P., Tay F. et al. Comparing safety of abrasion and tape-stripping as skin preparation in allergen-specific epicutaneous immunotherapy. J. Allergy Clin. Immunol. 2014, v. 134, p. 965-967.
  15. Tabar A.I., Echechipia S., Garcia B.E. et al. Double-blind comparative study of cluster and conventional immunotherapy schedules with Dermatophagoides pteronyssinus. J. Allergy Clin. Immunol. 2005, v. 116, p. 109-118.
  16. CMS update: Desensitizing vaccines. Br. Med. J. 1986; 293:948.
  17. Temino V.M., Wu P., Konig J., Fahrenholz J.M. Safety of multiple aeroallergen rush immunotherapy using a modified schedule. Allergy Asthma Proc. 2013, v. 34, p. 255-260.
  18. Rieker-Schwienbacher J., Nell M.J., Diamant Z. et al. Open-label parallel dose tolerability study of three subcutaneous immunotherapy regimens in house dust mite allergic patients. Clin. Transl. Allergy. 2013, v. 3, p. 42.
  19. Durham S.R., Walker S.M., Varga E.M. et al. Long-term clinical efficacy of grass-pollen immunotherapy. N. Engl. J. Med. 1999, v. 341, p. 468-475.
  20. Des Roches A., Paradis L., Knani J. et al. Immunotherapy with a standardized Dermatophagoides pteronyssinus extract. V. Duration of the efficacy of immunotherapy after its cessation. Allergy. 1996, v. 51, p. 430-433.
  21. Marogna M., Spadolini I., Massolo A. et al. Long-lasting effects of sublingual immunotherapy according to its duration: a 15-year prospective study. J. Allergy Clin. Immunol. 2010, v. 126, p. 969-975.
  22. Calderon M.A., Cox L., Casale T.B. et al. Multiple-allergen and single-allergen immunotherapy strategies in polysensitized patients: looking at the published evidence. J. Allergy Clin. Immunol. 2012, v. 129, p. 929-934.
  23. Cox L.S., Linnemann D.L., Nolte H. et al. Sublingual immunotherapy: a comprehensive review. J. Allergy Clin. Immunol. 2006, v. 117, p. 1021-1035.
  24. Passalacqua G., Baena-Cagnani C.E., Bousquet J. et al. Grading local side effects of sublingual immunotherapy for respiratory allergy: speaking the same language. J. Allergy Clin. Immunol. 2013, v. 132, p. 93-98.
  25. Cox L., Larenas-Linnemann D., Lockey R.F., Passalacqua G. Speaking the same language: the World Allergy Organization Subcutaneous Immunotherapy Systemic Reaction Grading System. J. Allergy Clin. Immunol. 2010, v. 125, p. 569-574.
  26. Coop C.A., Tankersley M.S. Patient perceptions regarding local reactions from allergen immunotherapy injections. Ann. Allergy Asthma Immunol. 2008, v. 101, p. 96-100.
  27. Kelso J.M. The rate of systemic reactions to immunotherapy injections is the same whether or not the dose is reduced after a local reaction. Ann. Allergy Asthma Immunol. 2004, v. 92, p. 225-227.
  28. Tankersley M.S., Butler K.K., Butler W.K., Goetz D.W. Local reactions during allergen immunotherapy do not require dose adjustment. J. Allergy Clin. Immunol. 2000, v. 106, p. 840-843.
  29. Roy S.R., Sigmon J.R., Olivier J. et al. Increased frequency of large local reactions among systemic reactors during subcutaneous allergen immunotherapy. Ann. Allergy Asthma Immunol. 2007, v. 99, p. 82-86.
  30. Amin H.S., Liss G.M., Bernstein D.I. Evaluation of near-fatal reactions to allergen immunotherapy injections. J. Allergy Clin. Immunol. 2006, v. 117, p. 169-175.
  31. Schiappoli M., Ridolo E., Senna G. et al. A prospective Italian survey on the safety of subcutaneous immunotherapy for respiratory allergy. Clin. Exp. Allergy. 2009, v. 39, p. 1569-1574.
  32. Passalacqua G., Guerra L., Compalati E., Canonica G.W The safety of allergen specific sublingual immunotherapy. Curr. Drug. Saf. 2007, v. 2, p. 117-123.
  33. Brozek J.L., Bousquet J., Baena-Cagnani C.E. et al. Allergic Rhinitis and its Impact on Asthma (ARIA) guidelines: 2010 revision. J. Allergy Clin. Immunol. 2010, v. 126, p. 466-476.
  34. Bousquet J., Schunemann H.J., Samolinski B. et al. Allergic Rhinitis and its Impact on Asthma (ARIA): achievements in 10 years and future needs. J. Allergy Clin. Immunol. 2012, v. 130, p. 1049-1062.
  35. Canonica G.W., Bousquet J., Casale T. et al. Sublingual immunotherapy: World Allergy Organization Position Paper 2009. Allergy. 2009, v. 64, p. 1-59.
  36. Canonica G.W, Cox L., Pawankar R. et al. Sublingual immunotherapy: World Allergy Organization position paper 2013 update. World Allergy Organ J. 2014, v. 7, p. 6. Российский Аллергологический ^^урнал № 1-2017
  37. Burks A.W., Calderon M.A., Casale T. et al. Update on allergy immunotherapy: American Academy of Allergy, Asthma & Immunology/European Academy of Allergy and Clinical Immunology/PRACTALL consensus report. J. Allergy Clin. Immunol. 2013, v. 131, p. 1288-1296.
  38. Malling H.J., Bousquet J. Subcutaneous immunotherapy for allergic rhinoconjunctivitis, allergic asthma, and prevention of allergic diseases. Clin. Allergy Immunol. 2008, v. 21, p. 343-358.
  39. Wilson D.R., Lima M.T., Durham S.R. Sublingual immunotherapy for allergic rhinitis: systematic review and meta-analysis. Allergy. 2005, v. 60, p. 4-12.
  40. Jacobsen L., Niggemann B., Dreborg S. et al. The PAT Investigator Group. Specific immunotherapy has long-term preventive effect of seasonal and perennial asthma: 10-year follow-up on the PAT study. Allergy. 2007, v. 62, p. 943-948.
  41. Des Roches A., Paradis L., Menardo J.L., Bouges S., Daures J.P., Bousquet J. Immunotherapy with a standardized Dermatophagoides pteronyssinus extract. VI. Specific immunotherapy prevents the onset of new sensitizations in children. J. Allergy Clin. Immunol. 1997, v. 99, p. 450-453.
  42. Purello-D’Ambrosio F., Gangemi S., Merendino R.A. et al. Prevention of new sensitizations in monosensitized subjects submitted to specific immunotherapy or not. A retrospective study. Clin. Exp. Allergy. 2001, v. 31, p. 1295-1302.
  43. Tahamiler R., Saritzali G., Canakcioglu S. Long-term efficacy of sublingual immunotherapy in patients with perennial rhinitis. Laryngoscope. 2007, v. 117, p. 965-969.
  44. Kim J.M., Lin S.Y., Suarez-Cuervo C. et al. Allergen-specific immunotherapy for pediatric asthma and rhinoconjunctivitis: a systematic review. Pediatrics. 2013, v. 131, p. 1155-1167.
  45. Schiappoli M., Ridolo E., Senna G. et al. A prospective Italian survey on the safety of subcutaneous immunotherapy for respiratory allergy. Clin. Exp. Allergy. 2009, v. 39, p. 1569-1574.
  46. Agache I., Akdis C., Jutel M., Virchow J.C. Untangling asthma phenotypes and endotypes. Allergy. 2012, v. 67, p. 835-846.
  47. Jutel M., Van de Veen W., Agache I., Azkur K.A. et al. Mechanisms of allergen-specific immunotherapy and novel ways for vaccine development. Allergol. Int. 2013, v. 62, p. 425-433.
  48. From the Global Strategy for Asthma Management and Prevention, Global Initiative for Asthma (GINA) 2014. Available at: http://www.ginasthma.org/. Accessed June 30, 2015.
  49. Mosbech H., Deckelmann R., de Blay F. et al. Standardized quality (SQ) house dust mite sublingual immunotherapy tablet (ALK) reduces inhaled corticosteroid use while maintaining asthma control: a randomized, double-blind, placebo-controlled trial. J. Allergy Clin. Immunol. 2014, v. 134, p. 568-575.
  50. Lin S.Y., Erekosima N., Suarez-Cuervo C. et al. Allergen-specific immunotherapy for the treatment of allergic rhinocon-junctivitis and/or asthma: comparative effectiveness review. Comparative Effectiveness Review No. 111. (Prepared by the Johns Hopkins University Evidence-based Practice Center under Contract No. 290-2007-10061-I.) AHRQ Publication No. 13-EHC061-EF. Rockville (MD): Agency for Healthcare Research and Quality. 2013.
  51. Abramson M.J., Puy R.M., Weiner J.M. Injection allergen immunotherapy for asthma. Cochrane Database Syst. Rev. 2010, v. (8): CD001186.
  52. Erekosima N., Suarez-Cuervo C., Ramanathan M. et al. Effectiveness of subcutaneous immunotherapy for allergic rhinoconjunctivitis and asthma: a systematic review. Laryngoscope. 2014, v. 124, p. 616-627.
  53. Lin S.Y., Erekosima N., Kim J.M. et al. Sublingual immunotherapy for the treatment of allergic rhinoconjunctivitis and asthma: a systematic review. JAMA. 2013, v. 309, p. 1278-1288.
  54. De Blay F., Kuna P., Prieto L. et al. SQ HDM SLITtablet (ALK) in treatment of asthma - post hoc results from a randomized trial. Respir. Med. 2014, v. 108, p. 1430-1437.
  55. Marogna M., Braidi C., Bruno M.E. et al. The contribution of sublingual immunotherapy to the achievement of control in birchrelated mild persistent asthma: a real-life randomized trial. Allergol. Immunopathol (Madr). 2013, v. 41, p. 216-224.
  56. Cox L., Nelson H., Lockey R. et al. Allergen immunotherapy: a practice parameter third update. J. Allergy Clin. Immunol. 2011, v. 127, p. 1-55.
  57. Calderon M.A., Cox L., Casale TB. et al. Multiple-allergen and single-allergen immunotherapy strategies in polysensitized patients: looking at the published evidence. J. Allergy Clin. Immunol. 2012, v. 129, p. 929-934.
  58. Calderon M.A., Simons F.E., Malling H.J. et al. Sublingual allergen immunotherapy: mode of action and its relationship with the safety profile. Allergy. 2012, v. 67, p. 302-311.
  59. Stelmach I., Sobocinska A., Majak P. et al. Comparison of the long-term efficacy of 3- and 5-year house dust mite allergen immunotherapy. Ann. Allergy Asthma Immunol. 2012, v. 109, p. 274-278.
  60. Passalacqua G., Guerra L., Compalati E., Canonica G.W. The safety of allergen specific sublingual immunotherapy. Curr. Drug. Saf. 2007, v. 2, p. 117-123.
  61. Penagos M., Passalacqua G., Compalati E. et al. Metaanalysis of the efficacy of sublingual immunotherapy in the treatment of allergic asthma in pediatric patients, 3 to 18 years of age. Chest. 2008, v. 133, p. 599-609.
  62. Werfel T., Breuer K., Rueff F. et al. Usefulness of specific immunotherapy in patients with atopic dermatitis and allergic sensitization to house dust mites: a multi-centre, randomized, dose-response study. Allergy. 2006, v. 61, p. 202-205.
  63. Bae J.M., Choi YY, Park C.O. et al. Efficacy of allergen-specific immunotherapy for atopic dermatitis: a systematic review and meta-analysis of randomized controlled trials. J. Allergy Clin. Immunol. 2013, v. 132, p. 110-117.
  64. Novak N., Bieber T, Hoffmann M. et al. Efficacy and safety of subcutaneous allergen-specific immunotherapy with depigmented polymerized mite extract in atopic dermatitis. J. Allergy Clin. Immunol. 2012, v. 130, p. 925-931.
  65. Gendelman S.R., Lang D.M. Specific immunotherapy in the treatment of atopic dermatitis: a systematic review using the GRADE system. Ann. Allergy Asthma Immunol. 2013, v. 111, p. 555-561.
  66. Pajno G.B., Caminiti L., Vita D. et al. Sublingual immunotherapy in mite-sensitized children with atopic dermatitis: a randomized, double-blind, placebo-controlled study. J. Allergy Clin. Immunol. 2007, v. 120, p. 164-170.
  67. Ring J., Alomar A., Bieber T. et al. Guidelines for treatment of atopic eczema (atopic dermatitis) Part II. J. Eur. Acad. Dermatol. Venereol. 2012, v. 26, p. 1176-1193.
  68. Darsow U. Allergen-specific immunotherapy for atopic eczema: updated. Curr. Opin. Allergy Clin. Immunol. 2012, v. 12, p. 665-669.
  69. Schofield A.T. A case of egg poisoning. Lancet. 1908, v. 1, p. 716.
  70. Nurmatov U., Venderbosch I., Devereux G. et al. Allergen-specific oral immunotherapy for peanut allergy. Cochrane Database Syst. Rev. 2012, v. 9: CD009014.
  71. Buchanan A.D., Green T.D., Jones S.M. et al. Egg oral immunotherapy in nonanaphylactic children with egg allergy. J. Allergy Clin. Immunol. 2007, v. 119, p. 199-205.
  72. Keet C.A., Fiischmeyer-Guerreiio P.A., Thyagarajan A. et al. The safety and efficacy of sublingual and oral immunotherapy for milk allergy. J. Allergy Clin. Immunol. 2012, v. 129, p. 448-455.
  73. Zuidmeer-Jongejan L., Fernandez-Rivas M., Poulsen L.K. et al. FAST: towards safe and effective subcutaneous immunotherapy of persistent life-threatening food allergies. Clin. Transl. Allergy. 2012, v. 2, p. 5.
  74. Burks A.W., Jones S.M., Wood R.A. et al. Oral immunotherapy for treatment of egg allergy in children. N. Engl. J. Med. 2012, v. 367, p. 233-243.
  75. Nadeau K.C., Kohli A., Iyengar S. et al. Oral immunotherapy and anti-IgE antibody-adjunctive treatment for food allergy. Immunol. Allergy Clin. North Am. 2012, v. 32, p. 111-133.
  76. Vickery B.P., Scurlock A.M., Kulis M. et al. Sustained unresponsiveness to peanut in subjects who have completed peanut oral immunotherapy. J. Allergy Clin. Immunol. 2014, v. 133, p. 468-475.
  77. Syed A., Garcia M.A., Lyu S.C. et al. Peanut oral immunotherapy results in increased antigen-induced regulatory T-cell function and hypomethylation of forkhead box protein 3 (FOXP3). J. Allergy Clin. Immunol. 2014, v. 133, p. 500-510.
  78. Nowak-Wegrzyn A., Bloom K.A., Sicherer S.H. et al. Tolerance to extensively heated milk in children with cow’s milk allergy. J. Allergy Clin. Immunol. 2008, v. 122, p. 342-347, p. 1-2.
  79. Kim J.S., Nowak-Wegrzyn A., Sicherer S.H. et al. Dietary baked milk accelerates the resolution of cow’s milk allergy in children. J. Allergy Clin. Immunol. 2011, v. 128, p. 125-131.
  80. De Silva D., Geromi M., Panesar S.S. et al. Acute and longterm management of food allergy: systematic review. Allergy. 2014, v. 69, p. 159-167.
  81. Muraro A., Werfel T., Hoffmann-Sommergruber K. et al. EAACI food allergy and anaphylaxis guidelines: diagnosis and management of food allergy. Allergy. 2014, v. 69, p. 1008-1025.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2017 Pharmarus Print Media

Согласие на обработку персональных данных с помощью сервиса «Яндекс.Метрика»

1. Я (далее – «Пользователь» или «Субъект персональных данных»), осуществляя использование сайта https://journals.rcsi.science/ (далее – «Сайт»), подтверждая свою полную дееспособность даю согласие на обработку персональных данных с использованием средств автоматизации Оператору - федеральному государственному бюджетному учреждению «Российский центр научной информации» (РЦНИ), далее – «Оператор», расположенному по адресу: 119991, г. Москва, Ленинский просп., д.32А, со следующими условиями.

2. Категории обрабатываемых данных: файлы «cookies» (куки-файлы). Файлы «cookie» – это небольшой текстовый файл, который веб-сервер может хранить в браузере Пользователя. Данные файлы веб-сервер загружает на устройство Пользователя при посещении им Сайта. При каждом следующем посещении Пользователем Сайта «cookie» файлы отправляются на Сайт Оператора. Данные файлы позволяют Сайту распознавать устройство Пользователя. Содержимое такого файла может как относиться, так и не относиться к персональным данным, в зависимости от того, содержит ли такой файл персональные данные или содержит обезличенные технические данные.

3. Цель обработки персональных данных: анализ пользовательской активности с помощью сервиса «Яндекс.Метрика».

4. Категории субъектов персональных данных: все Пользователи Сайта, которые дали согласие на обработку файлов «cookie».

5. Способы обработки: сбор, запись, систематизация, накопление, хранение, уточнение (обновление, изменение), извлечение, использование, передача (доступ, предоставление), блокирование, удаление, уничтожение персональных данных.

6. Срок обработки и хранения: до получения от Субъекта персональных данных требования о прекращении обработки/отзыва согласия.

7. Способ отзыва: заявление об отзыве в письменном виде путём его направления на адрес электронной почты Оператора: info@rcsi.science или путем письменного обращения по юридическому адресу: 119991, г. Москва, Ленинский просп., д.32А

8. Субъект персональных данных вправе запретить своему оборудованию прием этих данных или ограничить прием этих данных. При отказе от получения таких данных или при ограничении приема данных некоторые функции Сайта могут работать некорректно. Субъект персональных данных обязуется сам настроить свое оборудование таким способом, чтобы оно обеспечивало адекватный его желаниям режим работы и уровень защиты данных файлов «cookie», Оператор не предоставляет технологических и правовых консультаций на темы подобного характера.

9. Порядок уничтожения персональных данных при достижении цели их обработки или при наступлении иных законных оснований определяется Оператором в соответствии с законодательством Российской Федерации.

10. Я согласен/согласна квалифицировать в качестве своей простой электронной подписи под настоящим Согласием и под Политикой обработки персональных данных выполнение мною следующего действия на сайте: https://journals.rcsi.science/ нажатие мною на интерфейсе с текстом: «Сайт использует сервис «Яндекс.Метрика» (который использует файлы «cookie») на элемент с текстом «Принять и продолжить».